IEX · Earnings call · 2026Q3T · Full report

Guidance / Outlook

IDEX CORP /DE/ · 2026-10-28 · Importance 74 · Surprise 68 · In source text

On October 28, 2026, IDEX raised its full-year organic growth outlook to 6.5%–6.8%, from 5%–6%, and adjusted EPS guidance to $8.91–$8.96, from $8.70–$8.85. It tightened its full-year adjusted EBITDA margin outlook to 27.1%–27.3%, expects approximately $110 million of capital expenditures, and continues to target at least 100% free-cash-flow conversion. Management said its outlook reflects visibility in advantaged markets and stable-to-improving short-cycle industrial demand, and maintained high-30s to 40% incremental margins, net of reinvestment, as its longer-term framework; detailed 2027 guidance is expected on the Q4 call.

Key facts

• IDEX raised its 2026 adjusted EPS outlook by $0.16 at the midpoint to $8.91 to $8.96, from $8.70 to $8.85.
• IDEX expects 2026 capital expenditures of approximately $110 million and full-year free cash flow conversion of at least 100%.
• IDEX tightened its full-year 2026 adjusted EBITDA margin expectation to 27.1% to 27.3%.
• IDEX raised its full-year 2026 outlook following strong Q3 results.
• IDEX expects the legacy life-sciences platform roll-off to be largely lapped by year-end 2026.
• IDEX expects Q4 2026 margins to step down sequentially due largely to fewer production days and planned maintenance shutdowns that lower sales and margin.
• IDEX views high-30s to 40% incrementals, net of reinvestment, as the right framework for the company.
• IDEX expects high-30s to 40% incremental margins and sustainable double-digit earnings growth from its portfolio growth.

Impact estimates